Home
Product
Antibody
Biosimilar Antibodies
CDH6 (WO2016024195A1 Biosimilar) Recombinant Monoclonal Antibody

CDH6 (WO2016024195A1 Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA005055MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P55285

Target Names

CDH6

Alternative Names

CDH6; Cadherin-6; Kidney cadherin; K-cadherin

Species Reactivity

Human

Immunogen

Recombinant Human CDH6 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

0.01M PBS，pH7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

In stock
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is designed as a research-grade biosimilar to the reference antibody disclosed in patent WO2016024195A1, specifically targeting CDH6 (Cadherin-6, also known as K-cadherin). CDH6 is a calcium-dependent cell adhesion molecule belonging to the classical cadherin superfamily, playing critical roles in cell-cell recognition, tissue morphogenesis, and neural development. This protein exhibits restricted expression patterns in normal adult tissues but shows aberrant overexpression in various malignancies, including renal cell carcinoma, ovarian cancer, and certain pediatric tumors. The selective expression profile of CDH6 in cancer cells compared to normal tissues makes it an attractive target for oncology research and potential therapeutic development.

The reference antibody described in WO2016024195A1 was developed for targeting CDH6-expressing cancer cells and has been investigated for its potential in antibody-drug conjugate strategies and targeted cancer therapeutics. This biosimilar antibody serves as a valuable research tool for investigating CDH6 biology, evaluating its role in tumor progression and metastasis, and exploring CDH6-directed therapeutic approaches in preclinical cancer models.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.

Gene References into Functions

Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7), and cadherin-6 (CDH6) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR-129-2 and members of the miR-200 family (miR-200a, miR-200b, and miR-429) as novel tumor suppressors and oncomiRs, respectively, in CC PMID:27593557
The chromatin modifications were determined at five PRC2 targets commonly underexpressed in multiple myeloma (CIITA, CXCL12, GATA2, CDH6 and ICSBP/IRF8). The selected genes were confirmed to be underexpressed in MM compared to normal plasma cells. PMID:20634887

Hide All

Subcellular Location

Cell membrane; Single-pass type I membrane protein.

Tissue Specificity

Highly expressed in brain, cerebellum, and kidney. Lung, pancreas, and gastric mucosa show a weak expression. Also expressed in certain liver and kidney carcinomas.

Database Links

HGNC: 1765

UNIGENE: Hs.124776

KEGG: hsa:1004

STRING: 9606.ENSP00000265071

OMIM: 603007

Promotions